The Austin Health Research Ethics Committee has granted approval to Prana Biotechnology to initiate a 12-month Phase II Imaging trial in Australia to evaluate PBT2, an Alzheimer’s drug.
The double-blind and placebo-controlled trial will enrol 40 patients with prodromal or mild Alzheimer’s disease, and measure physical changes in the brains over 12 months of treatment with PBT2
Go deeper with GlobalData
The results will also be used to assess the positive effects of PBT2 on cognition reported in the earlier study.
In this study, cognition effects will be measured by the Neuropsychological Test Battery.
Prana executive chairman Geoffrey Kempler said, ”We believe that in this 12-month trial PBT2 will establish its credentials as a safe and effective treatment for Alzheimer’s disease,” Kempler added.
See Also:
The trial has been funded by the Alzheimer’s Drug Discovery Foundation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
